Occurrence of a Loss on Order in Master Cell Bank Development
First written in FY2020. 7 of 8 entries say "Materialised", first in FY2020. Latest entry: FY2023-Q3.
Kidswell Bio moved to the "Worse" side of this theme in 2020, 3 years before the typical company in this theme (2023).
41 other companies' latest entry also says "Other".
- FY2023-Q3Decrease in provision for loss on ordersAnnual report
「This was mainly due to increases of ¥975 million in long-term borrowings, including the portion due within 1 year, and ¥400 million in convertible bonds with stock acquisition rights, despite decreases of ¥475.243 million in the provision for contract losses and ¥216 million in contract liabilities.」
The provision for contract losses decreased by ¥475.243 million, leaving a zero balance on the balance sheet. - FY2022MaterialisedAnnual report
「Change in provision for contract losses (△ indicates a decrease) 96,000」
The provision for contract losses believed to relate to the master cell bank increased by ¥96 million during the period, bringing the period-end balance to ¥475.243 million. - FY2022-Q3MaterialisedAnnual report
「This was mainly due to a ¥96 million increase in the provision for contract losses, despite decreases of ¥400 million in convertible bonds with stock acquisition rights and ¥138.849 million in accounts payable.」
The provision for contract losses believed to relate to the master cell bank increased by ¥96 million, bringing the balance to ¥475.243 million. Additional contract losses have been recognized. - FY2022-Q2MaterialisedAnnual report
「This was mainly due to a ¥96 million increase in the provision for contract losses, despite decreases of ¥200 million in convertible bonds with stock acquisition rights and ¥281.741 million in accounts payable.」
The provision for contract losses increased by ¥96 million from ¥379.243 million at the end of the previous consolidated fiscal year to ¥475.243 million, and additional contract losses related to the master cell bank have been recognized. - FY2022-Q1MaterialisedAnnual report
「This was mainly due to a ¥96 million increase in the provision for contract losses, despite decreases of ¥200 million in convertible bonds with stock acquisition rights and ¥281.741 million in accounts payable.」
The provision for contract losses increased by ¥96 million from ¥379.243 million at the end of the previous consolidated fiscal year to ¥475.243 million, and additional contract losses related to the master cell bank have been recognized. - FY2021-Q3MaterialisedAnnual report
「Provision for contract losses 379,243」
The provision for contract losses increased from ¥355.243 million to ¥379.243 million, and additional contract losses related to the master cell bank have been recognized. - FY2021-Q2MaterialisedAnnual report
「Change in provision for contract losses (△ indicates a decrease) 24,000」
The provision for contract losses related to the master cell bank increased by ¥24 million on a cumulative basis for the current quarter, bringing the balance to ¥379.243 million. Additional contract losses have been recognized. - FY2020MaterialisedAnnual report
「In addition, to strengthen cooperation with partner companies and others toward the start of clinical trials, the company began efforts to establish a manufacturing process for finished products using MCB as the raw material. As a result, it recorded ¥355.243 million as an expense for the provision for contract losses, included in cost of sales, for the consolidated fiscal year, as the expected amount exceeded the original contract amount.」
Additional measures to establish a manufacturing process related to MCB resulted in expected losses exceeding the original contract amount, and the company recorded a ¥355.243 million provision for contract losses.